Meeting
2022 ASCO Annual Meeting
A biomarker enrichment trial of anti-EGFR agents in right primary tumor location (rPTL), RAS wild-type (RAS-wt) advanced colorectal cancer (aCRC): ARIEL (ISRCTN11061442).
Presenter
Christopher Williams, MBChB, MRCP
Leeds Cancer Centre
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Epidemiology/Outcomes
Clinical Trial Registration Number
11061442
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS3633)
DOI
10.1200/JCO.2022.40.16_suppl.TPS3633
Abstract #
TPS3633
Poster Bd #
424b
Abstract Disclosures
Similar Videos & Slides
Speaker: Panel Discussion
Videos & Slides
2022 ASCO Annual Meeting
Biomarker Utilization and Molecularly Targeted Therapy in RAS Wild-Type Colorectal Cancer
Speaker: Andrea Sartore-Bianchi, MD
Speaker: Panel Discussion
Videos & Slides
2024 ASCO Annual Meeting
First-in-human study of ABBV-400, a novel c-Met–targeting antibody-drug conjugate, in advanced solid tumors: Results in colorectal cancer.
Speaker: Manish Sharma, MD